CA125: Holy grail or a poisoned chalice

Nephron - Clinical Practice

Volumn 100, Issue 2, 2005, Pages

  Topley, Nicholas ^a   Michael, Daryn ^a   Bowen, Timothy ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; MESSENGER RNA;

ANTIGEN EXPRESSION; ANTIGEN STRUCTURE; DISEASE MARKER; EXON; HUMAN; NOTE; NUCLEOTIDE REPEAT; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN SECRETION; RNA SEQUENCE;

ANIMALS; BIOLOGICAL MARKERS; CA-125 ANTIGEN; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; MICE; PERITONEAL DIALYSIS;

EID: 20944436207     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085033     Document Type: Note

References (17)

1. Steinhauer HB, Günter B, Schollmeyer P: Stimulation of peritoneal synthesis of vasoactive prostaglandins during peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Invest 1985;15:1-5.
2. Steinhauer HB, Schollmeyer P: Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. Kidney Int 1986;29:584-590.
3. Visser CE, Brouwer-Steenbergen JJE, Betjes MGH, et al: Cancer antigen 125: A bulk marker for mesothelial cell mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995;10:64-69.
4. Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AAGM, et al: CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 1994;47:263-265.
5. Zeimet AG, Offner FA, Marth C, et al: Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 1997;17:3129-3131.
6. Brȩborowicz A, Brȩborowicz M, Pyda M, Polubinska A, Oreopoulos D: Limitations of CA125 as an index of peritoneal mesothelial cell mass - An in vitro study. Nephron Clin Pract 2005;100:c46-c51.
7. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, et al: Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997;51:888-893.
8. Lai KN, Lai KB, Szeto CC, et al: Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: Their relationship with transport parameters. Am J Kidney Dis 1997;29:699-705.
9. Rippe B, Simonsen O, Heimburger O, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-357.
10. Jones S, Holmes CJ, Krediet RT, et al: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001;59:1529-1538.
11. Williams JD, Topley N, Craig KJ, et al: The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-418.
12. Bast RC Jr, Feeney M, Lazarus H, et al: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-1337.
13. O'Brien TJ, Beard JB, Underwood LJ, et al: The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumor Biol 2001;22:348-366.
14. O'Brien TJ, Beard JB, Underwood LJ, et al: The CA 125 gene: A newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol 2002;23:154-169.
15. Yin BW, Dnistrian A, Lloyd KO: Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 2002;98:737-740.
16. Yin BW, Lloyd KO: Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-27375.
17. Monslow J, Williams JD, Guy CA, et al: Identification and analysis of the promoter region of the human hyaluronan synthase 2 gene. J Biol Chem 2004;279:20576-20581.